US FDA Approves Janssen’s IMBRUVICA to Treat Chronic Graft-Versus-Host Disease

The US Food and Drug Administration (FDA) of the United States has approved Janssen Pharmaceutical’s IMBRUVICA for the treatment of pediatric patients one year and older suffering with chronic graft-versus-host disease after the failure of more than one therapy. Janssen claims that, this milestone marks the first pediatric indication for IMBRUVICA, and the launch of […]

Continue Reading

North Carolina Facility of Glenmark Pharma Gets US FDA OAI Status

Glenmark Pharmaceuticals Limited has announced that the company has received Official Action Indicated (OAI) status from the US Food and Drug Administration (USFDA) for the Monroe, North Carolina (USA) facility. The OAI classification implies the inter-alia that the US FDA might withhold the approval of any pending product applications, and the supplements filed from the […]

Continue Reading

GE Healthcare and AWS Announced first European Cloud Deployment in UK

GE Healthcare and Amazon Web Services (AWS) announced the first European cloud deployment of Edison True PACS at the Royal Orthopaedic Hospital NHS Foundation Trust in Birmingham, the United Kingdom. This project is aiming to provide radiologists with intelligent productivity tools that provide help in enhancing reading speed, and reducing errors, with improve diagnostic precision, […]

Continue Reading